Plain-English translation of NCT04669171 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which is a vaccine designed to help your immune system fight slow-growing lymphomas (follicular lymphoma and marginal zone lymphoma). The researchers want to see if this medication works when given by itself, or combined with other approved cancer drugs like and . The trial will first test safety and find the right dose, then expand to see how well the treatment actually works.
Slow-growing lymphomas often come back or stop responding to standard treatments. This medication is being studied as a potentially new option to help patients whose cancer has returned or isn't responding to previous therapies.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you may receive the new vaccine as your only treatment, or you may start with the vaccine and then have other medications like or added based on how your lymphoma responds. The study begins with a safety phase to find the right dose, which will take several weeks. You'll need to visit the clinic regularly for blood tests, imaging scans, and to receive your treatment; the exact schedule depends on which study group you're in. Overall, you should expect ongoing clinic visits and close monitoring of your health throughout the trial.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
France